Hypocholesterolaemic activity of lupin peptides: Investigation on the crosstalk between human enterocytes and hepatocytes using a co-culture system including Caco-2 and HepG2 cells

Nutrients

Volumn 8, Issue 7, 2016, Pages

  Lammi, Carmen ^a   Zanoni, Chiara ^a   Ferruzza, Simonetta ^b   Ranaldi, Giulia ^b   Sambuy, Yula ^b   Arnoldi, Anna ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Food and Nutrition Research Centre   (Italy)

Author keywords

Bioactive food peptides; Cholesterol metabolism; Intestinal absorption; LDL receptor; Lupinus; PCSK9

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYPOCHOLESTEROLEMIC AGENT; KEXIN; LOW DENSITY LIPOPROTEIN RECEPTOR; SUBTILISIN; CHOLESTEROL; PCSK9 PROTEIN, HUMAN; PEPSIN A; PEPTIDE FRAGMENT; PLANT PROTEIN; PROPROTEIN CONVERTASE 9; PROTEIN HYDROLYSATE; TRYPSIN;

ARTICLE; CHOLESTEROL METABOLISM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTESTINE ABSORPTION; INTESTINE CELL; LIVER CELL; LUPIN; PROTEIN EXPRESSION; UPREGULATION; WESTERN BLOTTING; ANALYSIS; ANIMAL; CACO-2 CELL LINE; CELL COMMUNICATION; CHEMISTRY; COCULTURE; COMPARATIVE STUDY; DIETARY SUPPLEMENT; HEP-G2 CELL LINE; ISOLATION AND PURIFICATION; METABOLISM; PLANT SEED; SECRETION (PROCESS);

ANIMALS; ANTICHOLESTEREMIC AGENTS; CACO-2 CELLS; CELL COMMUNICATION; CHOLESTEROL; COCULTURE TECHNIQUES; DIETARY SUPPLEMENTS; ENTEROCYTES; HEP G2 CELLS; HEPATOCYTES; HUMANS; INTESTINAL ABSORPTION; LUPINUS; PEPSIN A; PEPTIDE FRAGMENTS; PLANT PROTEINS; PROPROTEIN CONVERTASE 9; PROTEIN HYDROLYSATES; SEEDS; TRYPSIN;

EID: 84979231549     PISSN: None     EISSN: 20726643     Source Type: Journal    
DOI: 10.3390/nu8070437     Document Type: Article

References (44)

1. Sujak, A, Kotlarz, A, Strobel, W. Compositional and nutritional evaluation of several lupi n seeds. Food Chem. 2006, 98, 711-719. [CrossRef]
2. Boschin, G, Arnoldi, A. Legumes are valuable sources of tocopherols. Food Chem. 2011, 127, 1199-1203. [CrossRef] [PubMed]
3. Siger, A, Czubinski, J, Kachlicki, P, Dwiecki, K, Lampart-Szczapa, E, Nogala-Kalucka, M. Antioxidsnt activity and phenolic content in three lupin speries. J. Food Compos. Anal. 2012, 25,190-197. [CrossRef]
4. Katagiri, Y, Ibrahim, R.K, Tahara, S. HPLC analysis of white lupin isoflavonoids. Biosci. Biotechnol. Biochem. 2000, 64, 1118-1125. [CrossRef] [PubMed]
5. Arnoldi, A, Boschin, G, Zanoni, C, Lammi, C. The health benefits of sweet lupin seed flours and isolated proteins. J. Funct. Foods 2015, 18, 550-563. [CrossRef]
6. Magni, C, Sessa, F, Accardo, E, Vanoni, M, Morazzoni, P, Scarafoni, A, Duranti, M. Conglutin gamma, a lupin seed protein, binds insulin in vitro and reduces plasma glucose levels of hyperglycemic rats. J. Nutr. Biochem. 2004, 15, 646-650. [CrossRef] [PubMed]
7. Bertoglio, J.C, Calvo, M.A, Hancke, J.L, Burgos, R.A, Riva, A, Morazzoni, P, Ponzone, C, Magni, C, Duranti, M. Hypoglycemic effect of lupin seedconglutin in experimental animals and healthy human subjects. Fitoterapia 2011, 82, 933-938. [CrossRef] [PubMed]
8. Boschin, G, Scigliuolo, G.M, Resta, D, Arnoldi, A. ACE-inhibitory activity of enzymatic protein hydrolysates from lupin and other legumes. Food Chem. 2014, 145, 34-40. [CrossRef] [PubMed]
9. Lee, Y.P, Mori, T.A, Puddey, I.B, Sipsas, S, Ackland, T.R, Beilin, L.J, Hodgson, J.M. Effects of lupin kernel flour-enriched bread on blood pressure: A controlled intervention study. Am. J. Clin. Nutr. 2009, 89, 766-772. [CrossRef] [PubMed]
10. Sirtori, C.R, Lovati, M.R, Manzoni, C, Castiglioni, S, Duranti, M, Magni, C, Morandi, S, D’Agostina, A, Arnoldi, A. Proteins of white lupin seed, a naturally isoflavone-poor legume, reduce cholesterolemia in rats and increase LDL receptor activity in HepG2 cells. J. Nutr. 2004, 134, 18-23. [PubMed]
11. Bettzieche, A, Brandsch, C, Schmidt, M, Weisse, K, Eder, K, Stangl, G. Differing effect of protein isolates from different cultivars of blue lupin on plasma lipoproteins of hypercholesterolemic rats. Biosci. Biotechnol. Biochem. 2008, 72, 3114-3121. [CrossRef] [PubMed]
12. Marchesi, M, Parolini, C, Diani, E, Rigamonti, E, Cornelli, L, Arnoldi, A, Sirtori, C.R, Chiesa, G. Hypolipidaemic and anti-atherosclerotic effects of lupin proteins in a rabbit model. Br. J. Nutr. 2008, 100, 707-710. [CrossRef] [PubMed]
13. Fontanari, G.G, Batistuti, J, da Cruz, R, Saldiva, P, Areas, J. Cholesterol-lowering effect of whole lupin (Lupinus albus) seed and its protein isolate. Food Chem. 2012, 132, 1521-1526. [CrossRef]
14. Bähr, M, Fechner, A, Kiehntopf, M, Jahreis, G. Consuming a mixed diet enriched with lupin protein beneficially affects plasma lipids in hypercholesterolemic subjects: A randomized controlled trial. Clin. Nutr. 2015, 34, 7-14. [CrossRef] [PubMed]
15. Sirtori, C.R, Triolo, M, Bosisio, R, Bondioli, A, Calabresi, L, De Vergori, V, Gomaraschi, M, Mombelli, G, Pazzucconi, F, Zacherl, C, et al. Hypocholesterolaemic effects of lupin protein and pea protein/fibre combinations in moderately hypercholesterolaemic individuals. Br. J. Nutr. 2012, 107, 1176-1183. [CrossRef] [PubMed]
16. Lammi, C, Zanoni, C, Scigliuolo, G.M, D’Amato, A, Arnoldi, A. Lupin Peptides Lower Low-Density Lipoprotein (LDL) Cholesterol through an Up-regulation of the LDL Receptor/Sterol Regulatory Element Binding Protein 2 (SREBP2) Pathway at HepG2 Cell Line. J. Agric. Food Chem. 2014, 62, 7151-7159. [CrossRef] [PubMed]
17. Gu, H.M, Zhang, D.W. Hypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9. J. Biomed. Res. 2015, 29, 356-361. [PubMed]
18. Stein, E.A, Raal, F.J. Lipid-lowering drug therapy for CVD prevention: Looking into the future. Curr. Cardiol. Rep. 2015, 17, 104. [CrossRef] [PubMed]
19. Zhang, L, Song, K, Zhu, M, Shi, J, Zhang, H, Xu, L, Chen, Y. Proprotein convertase subtilisin/kexin type 9 (PCSK9) in lipid metabolism, atherosclerosis and ischemic stroke. Int. J. Neurosci. 2016, 126, 675-680. [CrossRef] [PubMed]
20. Giunzioni, I, Tavori, H. New developments in atherosclerosis: Clinical potential of PCSK9 inhibition. Vasc. Health Risk. Manag. 2015, 11, 493-501. [PubMed]
21. Lammi, C, Zanoni, C, Calabresi, L, Arnoldi, A. Lupin protein exerts cholesterol-lowering effects targeting PCSK9: From clinical evidences to elucidation of the in vitro molecular mechanism using HepG2 cells. J. Funct. Foods 2016, 23, 230-240. [CrossRef]
22. Sambuy, Y, De Angelis, I, Ranaldi, G, Scarino, M.L, Stammati, A, Zucco, F. The Caco-2 cell line as a model of the intestinal barrier: Influence of cell and culture-related factors on Caco-2 cell functional characteristics. Cell Biol. Toxicol. 2005, 21, 1-26. [CrossRef] [PubMed]
23. Ferruzza, S, Scarino, M.L, Gambling, L, Natella, F, Sambuy, Y. Biphasic effect of iron on human intestinal Caco-2 cells: Early effect on tight junction permeability with delayed onset of oxidative cytotoxic damage. Cell. Mol. Biol. (Noisy-le-Grand) 2003, 49, 89-99.
24. Gallego, M, Grootaert, C, Mora, L, Aristoy, M.C, Van Camp, J, Toldra, F. Transepithelial transport of dry-cured ham peptides with ACE inhibitory activity through a Caco-2 cell monolayer. J. Funct. Foods 2016, 21, 388-395. [CrossRef]
25. Lammi, C, Aiello, G, Vistoli, G, Zanoni, C, Arnoldi, A, Sambuy, Y, Ferruzza, S, Ranaldi, G. A multidisciplinary investigation on the bioavailability and activity of peptides from lupin protein. J. Funct. Foods 2016, 24, 297-306. [CrossRef]
26. Havekes, L, van Hinsbergh, V, Kempen, H.J, Emeis, J. The metabolism in vitro of human low-density lipoprotein by the human hepatoma cell line Hep G2. Biochem. J. 1983, 214, 951-958. [CrossRef] [PubMed]
27. Javitt, N.B. Hep G2 cells as a resource for metabolic studies: Lipoprotein, cholesterol, and bile acids. FASEB J. 1990, 4, 161-168. [PubMed]
28. Vrins, C.L. From blood to gut: Direct secretion of cholesterol via transintestinal cholesterol efflux. World J. Gastroenterol. 2010, 16, 5953-5957. [PubMed]
29. Van der Veen, J.N, van Dijk, T.H, Vrins, C.L, van Meer, H, Havinga, R, Bijsterveld, K, Tietge, U.J, Groen, A.K, Kuipers, F. Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol. J. Biol. Chem. 2009, 284, 19211-19219. [CrossRef] [PubMed]
30. Van der Velde, A.E, Vrins, C.L, van den Oever, K, Kunne, C, Oude Elferink, R.P, Kuipers, F, Groen, A.K. Direct intestinal cholesterol secretion contributes significantly to total fecal neutral sterol excretion in mice. Gastroenterology 2007, 133, 967-975. [CrossRef] [PubMed]
31. Natoli, M, Leoni, B.D, D’Agnano, I, D’Onofrio, M, Brandi, R, Arisi, I, Zucco, F, Felsani, A. Cell growing density affects the structural and functional properties of Caco-2 differentiated monolayer. J. Cell. Physiol. 2011, 226, 1531-1543. [CrossRef] [PubMed]
32. Ferruzza, S, Rossi, C, Scarino, M.L, Sambuy, Y. A protocol for differentiation of human intestinal Caco-2 cells in asymmetric serum-containing medium. Toxicol. in Vitro 2012, 26, 1252-1255. [CrossRef] [PubMed]
33. Clark, L.T. Optimizing lipid lowering in patients at risk. Clin. Cardiol. 2004, 27, 322-326. [CrossRef] [PubMed]
34. Horton, J.D, Goldstein, J.L, Brown, M.S. SREBPs: Transcriptional mediators of lipid homeostasis. Cold Spring Harb. Symp. Quant. Biol. 2002, 67, 491-498. [CrossRef] [PubMed]
35. Edwards, P.A, Tabor, D, Kast, H.R, Venkateswaran, A. Regulation of gene expression by SREBP and SCAP. Biochim. Biophys. Acta 2000, 1529, 103-113. [CrossRef]
36. Levy, E, Ben Djoudi Ouadda, A, Spahis, S, Sane, A.T, Garofalo, C, Grenier, É, Emonnot, L, Yara, S, Couture, P, Beaulieu, J.F, et al. PCSK9 plays a significant role in cholesterol homeostasis and lipid transport in intestinal epithelial cells. Atherosclerosis 2013, 227, 297-306. [PubMed]
37. Pathak, R.K, Yokode, M, Hammer, R.E, Hofmann, S.L, Brown, M.S, Goldstein, J.L, Anderson, R.G. Tissue-specific sorting of the human LDL receptor in polarized epithelia of transgenic mice. J. Cell Biol. 1990, 111, 347-359. [CrossRef] [PubMed]
38. Goldstein, J.L, Brown, M.S. Regulation of the mevalonate pathway. Nature 1990, 343, 425-430. [CrossRef] [PubMed]
39. Pallottini, V, Martini, C, Pascolini, A, Cavallini, G, Gori, Z, Bergamini, E, Incerpi, S, Trentalance, A. 3-Hydroxy-3-methylglutaryl coenzyme A reductase deregulation and age-related hypercholesterolemia: A new role for ROS. Mech. Ageing Dev. 2005, 126, 845-851. [CrossRef] [PubMed]
40. Ching, Y.P, Davies, S.P, Hardie, D.G. Analysis of the specificity of the AMP-activated protein kinase by site-directed mutagenesis of bacterially expressed 3-hydroxy 3-methylglutaryl-CoA reductase, using a single primer variant of the unique-site-elimination method. Eur. J. Biochem. 1996, 237, 800-808. [CrossRef] [PubMed]
41. Seidah, N.G, Awan, Z, Chrétien, M, Mbikay, M. PCSK9: A key modulator of cardiovascular health. Circ. Res. 2014, 114, 1022-1036. [CrossRef] [PubMed]
42. Rashid, S, Tavori, H, Brown, P.E, Linton, M.F, He, J, Giunzioni, I, Fazio, S. Proprotein convertase subtilisin kexin type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein receptor-dependent and -independent mechanisms. Circulation 2014, 130, 431-441. [CrossRef] [PubMed]
43. Le May, C, Kourimate, S, Langhi, C, Chétiveaux, M, Jarry, A, Comera, C, Collet, X, Kuipers, F, Krempf, M, Cariou, B, et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler. Thromb. Vasc. Biol. 2009, 29, 684-690. [CrossRef] [PubMed]
44. Le May, C, Berger, J.M, Lespine, A, Pillot, B, Prieur, X, Letessier, E, Hussain, M.M, Collet, X, Cariou, B, Costet, P. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 1484-1493. [CrossRef] [PubMed]